Cutler Group LP Immunovant, Inc. Call Options Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$31.31 - $44.19 $137,764 - $194,436	4,400 Added 488.89%	5,300 $17,000
Q3 2023 Nov 07, 2023	BUY	$18.55 - $39.96 $16,695 - $35,964	900 New	900 $2,000
Q3 2021 Oct 26, 2021	SELL	$7.01 - $11.37 $14,020 - $22,740	-2,000 Closed	0 $0
Q2 2021 Jul 19, 2021	SELL	$9.4 - $16.85 $7,520 - $13,480	-800 Reduced 28.57%	2,000 $0
Q1 2021 Apr 26, 2021	BUY	$13.08 - $49.6 $36,624 - $138,880	2,800 New	2,800 $5,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.